Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kazia Therapeutics Limited (Kazia Therapeutics) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The companys product pipeline includes PI3K GDC-0084 and Cantrixil (TRX-E-002-1). GDC-0084 is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme which cel is an aggressive form of primary brain cancer in adults. GDC-0084 is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule which acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. It develops molecules in collaborations with various research institutes. Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd Key Recent Developments

Jan 15,2019: Kazia receives $2.2 million R&D cash rebate
Feb 19,2018: Kazia Change Of Registered Office And Business Address

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company
Kazia Therapeutics Ltd - Key Facts
Kazia Therapeutics Ltd - Key Employees
Kazia Therapeutics Ltd - Key Employee Biographies
Kazia Therapeutics Ltd - Major Products and Services
Kazia Therapeutics Ltd - History
Kazia Therapeutics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Kazia Therapeutics Ltd - Business Description
Kazia Therapeutics Ltd - Corporate Strategy
Kazia Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Kazia Therapeutics Ltd - Strengths
Kazia Therapeutics Ltd - Weaknesses
Kazia Therapeutics Ltd - Opportunities
Kazia Therapeutics Ltd - Threats
Kazia Therapeutics Ltd - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Kazia Therapeutics Ltd, Recent Deals Summary
Section 5 Companys Recent Developments
Jan 15, 2019: Kazia receives $2.2 million R&D cash rebate
Feb 19, 2018: Kazia Change Of Registered Office And Business Address
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Kazia Therapeutics Ltd, Key Facts
Kazia Therapeutics Ltd, Key Employees
Kazia Therapeutics Ltd, Key Employee Biographies
Kazia Therapeutics Ltd, Major Products and Services
Kazia Therapeutics Ltd, History
Kazia Therapeutics Ltd, Subsidiaries
Kazia Therapeutics Ltd, Key Competitors
Kazia Therapeutics Ltd, Ratios based on current share price
Kazia Therapeutics Ltd, Annual Ratios
Kazia Therapeutics Ltd, Annual Ratios (Cont...1)
Kazia Therapeutics Ltd, Interim Ratios
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Kazia Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Kazia Therapeutics Ltd, Performance Chart (2015 - 2019)
Kazia Therapeutics Ltd, Ratio Charts
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available